51 related articles for article (PubMed ID: 22521528)
21. Implementation of image-guided radiotherapy.
Franks KN; McNair HA
Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):625-6. PubMed ID: 22801517
[No Abstract] [Full Text] [Related]
22. (S039) High-Resolution 4D Ventilation and Perfusion PET/CT Facilitates Functionally Adapted Intensity-Modulated Radiation Therapy (IMRT) in Lung Cancer.
Oncology (Williston Park); 2015 Apr; 29(4 Suppl 1):. PubMed ID: 25930756
[No Abstract] [Full Text] [Related]
23. Editorial Comment: PET/CT-Guided Tumor Ablations-The Merits, the Methods, and the Mysteries.
Rostambeigi N
AJR Am J Roentgenol; 2024 Mar; ():. PubMed ID: 38506545
[No Abstract] [Full Text] [Related]
24. Role of Positron Emission Tomography/Computed Tomography in Epithelial Ovarian Cancer.
Chandra R; Kumari S; Bhatla N; Kumar R; Tiwari A; Sachani H; Kumar L
Indian J Nucl Med; 2023; 38(4):366-375. PubMed ID: 38390547
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature.
Allahqoli L; Hakimi S; Laganà AS; Momenimovahed Z; Mazidimoradi A; Rahmani A; Fallahi A; Salehiniya H; Ghiasvand MM; Alkatout I
J Imaging; 2023 Oct; 9(10):. PubMed ID: 37888330
[TBL] [Abstract][Full Text] [Related]
26. Role of DEP domain-containing protein 1B (DEPDC1B) in epithelial ovarian cancer.
Wu Y; Yin H; Zhang X; Shen R; Zhu X; Jia M
J Cancer; 2023; 14(5):784-792. PubMed ID: 37056386
[TBL] [Abstract][Full Text] [Related]
27. EANM guideline on the role of 2-[
Delgado Bolton RC; Aide N; Colletti PM; Ferrero A; Paez D; Skanjeti A; Giammarile F
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3286-3302. PubMed ID: 34215923
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of the Metabolic Profiling of the BIMRT Utilizing 18F FDG PET-CT.
Dang YZ; Zhang DX; Wang GD; Zhao HL; Huang SG; Li J
Technol Cancer Res Treat; 2020; 19():1533033820960723. PubMed ID: 32990157
[TBL] [Abstract][Full Text] [Related]
29. Metastatic Ovarian Cancer Presenting as Inflammatory Breast Cancer: A Case Report.
Abu-Tineh M; Elmalik H; Yassin MA
Case Rep Oncol; 2020; 13(2):867-874. PubMed ID: 32884533
[TBL] [Abstract][Full Text] [Related]
30.
Dang YZ; Li X; Ma YX; Li XL; Yang T; Lu WL; Huang SG
Oncol Lett; 2019 Jan; 17(1):149-158. PubMed ID: 30655750
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of platinum refractory ovarian clear cell carcinoma with secondary cytoreductive surgery and implantable transponder placement to facilitate targeted volumetric arc radiation therapy.
Fehniger J; Schiff PB; Pothuri B
Gynecol Oncol Rep; 2019 Feb; 27():11-14. PubMed ID: 30555884
[TBL] [Abstract][Full Text] [Related]
32. Normal Variants and Pitfalls Encountered in PET Assessment of Gynecologic Malignancies.
Yu JQ; Doss M; Alpaugh RK
PET Clin; 2018 Apr; 13(2):249-268. PubMed ID: 29482753
[TBL] [Abstract][Full Text] [Related]
33. Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.
Shang AQ; Wu J; Bi F; Zhang YJ; Xu LR; Li LL; Chen FF; Wang WW; Zhu JJ; Liu YY
Cancer Biol Ther; 2017 May; 18(5):314-322. PubMed ID: 28448787
[TBL] [Abstract][Full Text] [Related]
34. An update on the role of PET/CT and PET/MRI in ovarian cancer.
Khiewvan B; Torigian DA; Emamzadehfard S; Paydary K; Salavati A; Houshmand S; Werner TJ; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1079-1091. PubMed ID: 28180966
[TBL] [Abstract][Full Text] [Related]
35. Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up.
Rusu D; Carlier T; Colombié M; Goulon D; Fleury V; Rousseau N; Berton-Rigaud D; Jaffre I; Kraeber-Bodéré F; Campion L; Rousseau C
Front Med (Lausanne); 2015; 2():46. PubMed ID: 26258124
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of pre-therapy (18)F-FDG PET/CT for the outcome of (18)F-FDG PET-guided radiotherapy in patients with head and neck cancer.
Picchio M; Kirienko M; Mapelli P; Dell'Oca I; Villa E; Gallivanone F; Gianolli L; Messa C; Castiglioni I
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):21-31. PubMed ID: 23990143
[TBL] [Abstract][Full Text] [Related]
37. PET/CT scanning guided intensity-modulated radiotherapy in treatment of recurrent ovarian cancer.
Du XL; Jiang T; Sheng XG; Li QS; Wang C; Yu H
Eur J Radiol; 2012 Nov; 81(11):3551-6. PubMed ID: 22521528
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
[TBL] [Abstract][Full Text] [Related]
39. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT scans for diagnosing ovarian cancer recurrence.
Kitajima K; Ueno Y; Suzuki K; Kita M; Ebina Y; Yamada H; Senda M; Maeda T; Sugimura K
Eur J Radiol; 2012 Nov; 81(11):3557-62. PubMed ID: 22534465
[TBL] [Abstract][Full Text] [Related]
40. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer.
Chung HH; Kim JW; Kang KW; Park NH; Song YS; Chung JK; Kang SB
Eur J Radiol; 2012 Aug; 81(8):e817-22. PubMed ID: 22595504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
